Innate Pharma Files Routine 6-K, Confirms 20-F Reporting

Ticker: IPHYF · Form: 6-K · Filed: Feb 21, 2024 · CIK: 1598599

Innate Pharma SA 6-K Filing Summary
FieldDetail
CompanyInnate Pharma SA (IPHYF)
Form Type6-K
Filed DateFeb 21, 2024
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: regulatory-filing, foreign-issuer, compliance

TL;DR

**Innate Pharma just filed a standard 6-K, confirming their foreign private issuer status and 20-F annual reporting.**

AI Summary

Innate Pharma S.A. (Commission File Number: 001-39084) filed a Form 6-K on February 21, 2024, indicating its status as a foreign private issuer. The company, based at 117 Avenue de Luminy, BP 30191, 13009 Marseille, France, confirmed it files annual reports under Form 20-F. This filing serves as a routine report under the Securities Exchange Act of 1934.

Why It Matters

This filing confirms Innate Pharma's ongoing compliance with SEC reporting requirements as a foreign private issuer, providing transparency to investors.

Risk Assessment

Risk Level: low — This is a routine administrative filing with no new material information or changes in company operations.

Key Players & Entities

  • Innate Pharma S.A. (company) — registrant
  • February 21, 2024 (date) — date of report
  • 001-39084 (other) — Commission File Number
  • 117 Avenue de Luminy—BP 30191 (other) — principal executive office address
  • 13009 Marseille, France (other) — principal executive office city and country

FAQ

What type of report did Innate Pharma S.A. file?

Innate Pharma S.A. filed a Form 6-K, which is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.

What is the Commission File Number for Innate Pharma S.A.?

The Commission File Number for Innate Pharma S.A. is 001-39084.

What is the date of this report?

The date of this report is February 21, 2024.

Does Innate Pharma S.A. file annual reports under Form 20-F or Form 40-F?

Innate Pharma S.A. indicates by check mark that it files annual reports under cover of Form 20-F.

What is the business address of Innate Pharma S.A. as stated in the filing?

The business address of Innate Pharma S.A. is 117 Avenue de Luminy—BP 30191, 13009 Marseille, France.

Filing Stats: 205 words · 1 min read · ~1 pages · Grade level 10.5 · Accepted 2024-02-21 06:00:53

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INNATE PHARMA S.A. Date February 21, 2024 By s HERVE BRAILLY Name Herv Brailly Title Chairman of the Executive Board and Chief Executive

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.